An Open Label, Randomized, Single Dose, Parallel-group, Phase 1 Study to Evaluate the Pharmacokinetics and Safety Following Subcutaneous Administration of DWJ108J in Patients With Prostate Cancer
Latest Information Update: 07 Jan 2019
At a glance
- Drugs Leuprorelin (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Pharmacokinetics
- Sponsors Daewoong Pharmaceutical
- 06 Feb 2017 New trial record